Inflammatory marker profiles vary by BMI across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis - Takeaways - MDSpire

Profiles of Inflammatory Markers Differ by Body Mass Index in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis

  • By

  • Stephen A. Shields

  • Ann Von Holle

  • Ruthvik Padival

  • Joseph F. Merola

  • Rachael Zuckerman

  • Jeff T. Mohl

  • Elizabeth L. Ciemins

  • July 17, 2026

Share

  • 1

    Obesity is linked to chronic low-grade inflammation, affecting systemic inflammatory markers in immune-mediated inflammatory diseases (IMIDs).

  • 2

    A longitudinal study analyzed 17,710 patients with Crohn’s disease, ulcerative colitis, psoriasis, or psoriatic arthritis over five years.

  • 3

    Patients with obesity showed significantly higher C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) compared to healthy-weight individuals.

  • 4

    Elevations in CRP and ESR persisted over five years, while ferritin levels showed near null associations across all conditions studied.

  • 5

    The findings suggest that excess adiposity contributes to systemic inflammatory burden in IMIDs, warranting further investigation.

Original Source(s)

Inflammatory marker profiles vary by BMI across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis

  • by Stephen A. Shields, Ann Von Holle, Ruthvik Padival, Joseph F. Merola, Rachael Zuckerman, Jeff T. Mohl, Elizabeth L. Ciemins

  • July 17, 2026

Related Content

Efficacy Comparison of Cycling Versus Transitioning to IL-17 Inhibitors Following Initial TNF Inhibitor Failure in Psoriatic Arthritis: A Multicenter Real-World Analysis

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.